Jin Song, Liu Dai-Hong, Xu Lan-Ping, Chen Huan, Chen Yu-Hong, Qin Ya-Zhen, Liu Yan-Rong, Liu Kai-Yan, Huang Xiao-Jun
Institute of Hematology, People's Hospital of Peking University, Beijing 100044, China.
Zhonghua Nei Ke Za Zhi. 2008 Jul;47(7):578-81.
To evaluate preliminarily the significance of dynamic detection of Wilms' tumor gene (WT1) expression level on monitoring minimal residual disease (MRD) and predicting clinical relapse in patients of malignancy following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
WT1 expression level was measured with real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) method on 102 bone marrow specimens from 31 patients following allo-HSCT. WT1 expression level was determined as the ratio of WT1 mRNA to ABL mRNA times 100%.
The levels of WT1 expression showed significant difference between the relapsed group and the non-relapsed group (P < 0.01), with 0.80% and 0.17% as their median expression level respectively. After dynamic measuring WT1 expression level on patients in the relapsed group, the level was found to increase significantly as compared with those during or before the clinical hematological relapse, both being > 1.0%. The level at the time of relapse was significantly higher than the latest previous one (P < 0.05).
Dynamic detection of WT1 expression level with RQ-RT-PCR may be of help in monitoring MRD and warning clinical relapse on the patients following allo-HSCT.
初步评估动态检测肾母细胞瘤基因（WT1）表达水平在监测异基因造血干细胞移植（allo-HSCT）后恶性肿瘤患者微小残留病（MRD）及预测临床复发中的意义。
采用实时定量逆转录聚合酶链反应（RQ-RT-PCR）法检测31例allo-HSCT后患者的102份骨髓标本中WT1的表达水平。WT1表达水平以WT1 mRNA与ABL mRNA的比值乘以100%来确定。
复发组与未复发组WT1表达水平差异有统计学意义（P<0.01），中位数表达水平分别为0.80%和0.17%。对复发组患者动态检测WT1表达水平，发现其水平较临床血液学复发时或复发前明显升高，均>1.0%。复发时的水平明显高于上一次最近检测时的水平（P<0.05）。
采用RQ-RT-PCR动态检测WT1表达水平可能有助于监测allo-HSCT后患者的MRD及预警临床复发。
